Cytek Biosciences (CTKB) Gains from Sales and Divestitures (2022 - 2023)
Cytek Biosciences posted quarterly Gains from Sales and Divestitures of $260297.0 for Q2 2023, up 238.09% year-on-year from $76990.0 in Q2 2022, and up 218.84% on a QoQ basis from $81639.0 in Q1 2023.
Cytek Biosciences (CTKB) has 2 years of Gains from Sales and Divestitures data on file, last reported at $260297.0 in Q2 2023.
- For the quarter ending Q2 2023, Gains from Sales and Divestitures rose 238.09% year-over-year to $260297.0; the trailing twelve-month figure through Jun 2023 stood at $260297.0 (up 238.09% YoY), and the FY2022 full-year result was $215433.0, changed N/A from the prior year.
- Gains from Sales and Divestitures for Q2 2023 stood at $260297.0, up from $81639.0 in the prior quarter.
- Across five years, Gains from Sales and Divestitures topped out at $260297.0 in Q2 2023 and bottomed at $76990.0 in Q2 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Cytek Biosciences | - | - | 21.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 260,297.00 |
| Jun 30, 2023 | 260,297.00 |
| Mar 31, 2023 | 81,639.00 |
| Mar 31, 2023 | 81,639.00 |
| Dec 31, 2022 | 215,433.00 |
| Dec 31, 2022 | 215,433.00 |
| Sep 30, 2022 | 135,476.00 |
| Sep 30, 2022 | 135,476.00 |
| Jun 30, 2022 | 76,990.00 |
| Jun 30, 2022 | 76,990.00 |